Patients who had not yet displayed any symptoms had several tumors detected by a blood test. What GRAIL’s Pathfinder Study has accomplished might revolutionize cancer detection. Nearly 1% of the participants were in the test. Which was carried out on 6,662 people by the healthcare organization focusing on cancer screening, had cancer.
Research about a blood test
The research, which was conducted on individuals 50 years of age or older, was presented at the Paris ESMO Congress in 2022.
Multi-Cancer Early Detection (MCED) test is the name of the test. According to researchers, earlier iterations of the test were improved to provide a more precise test that solely considers cancer. The earlier model also picked up on pretty typical pre-malignant hematologic abnormalities.
According to GRAIL’s chief medical officer Jeffrey Venstrom, MD, MCED testing identified twice as many tumors as conventional screening. He stated in a statement, “These comprised Stage I malignancies of the liver, small intestine, and uterus, as well as Stage II pancreatic, bone, and oropharyngeal tumors.
Surprisingly, 70% of the study’s participants had cancer forms for which there is now no accessible conventional cancer screening. Cancer signals in 92 individuals 35 had 36 different tumors.
According to researchers, the prediction of the cancer signal’s origin had a 97% accuracy rate. The new blood test may enhance cancer detection and result in more effective therapeutic approaches.
Read more About: Foxconn signs a $19.4 billion agreement to produce semiconductors in India